Product Name: Nelipcpimut-S
CAS No: 160212-35-1
Purity: 95%
Molar Mass: 995.21
Chemical Formula: C50H78N10O11
Synonyms: Neuvax
Storage: Store at -20℃
Sequence: KIFGSLAFL
Target: HER2
Application: Nelipepimut-S(CAS: 160212-35-1), a cancer vaccine, consists of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein. This vaccine exhibits potential immunomodulating and antineoplastic activities. Administered via intradermal injection, nelipepimut-S has the capability to stimulate a specific cytotoxic T-lymphocyte (CTL) response targeted against HER2/neu-expressing tumor cells. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is frequently overexpressed in various types of tumor cells and is closely implicated in tumorigenesis. The mechanism of action of nelipepimut-S revolves around its ability to induce an immune response specifically against HER2/neu-expressing cancer cells. By targeting HER2/neu, which is often overexpressed in tumors, the vaccine aims to trigger the activation and proliferation of cytotoxic T-lymphocytes, which play a crucial role in recognizing and eliminating cancerous cells. This targeted immune response against HER2/neu-positive tumor cells can potentially halt tumor growth and lead to tumor regression. Nelipepimut-S holds promise as a therapeutic option for various cancers characterized by HER2/neu overexpression, including breast cancer and gastric cancer. Clinical studies have demonstrated its safety and efficacy in stimulating immune responses against HER2/neu-positive tumors, offering a potential avenue for improving outcomes in patients with these malignancies. Additionally, its immunomodulating properties may complement existing treatment modalities such as chemotherapy and targeted therapy, potentially enhancing overall therapeutic efficacy and patient outcomes.
